---
document_datetime: 2025-12-02 04:52:16
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ofev.html
document_name: ofev.html
version: success
processing_time: 0.1283882
conversion_datetime: 2025-12-27 18:01:21.671785
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ofev

[RSS](/en/individual-human-medicine.xml/65868)

##### Authorised

This medicine is authorised for use in the European Union

nintedanib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ofev](#news-on)
- [More information on Ofev](#more-information-on-ofev-1123)
- [More information on Ofev](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Ofev is a medicine used to treat:

- adults with idiopathic pulmonary fibrosis (IPF), a disease of unknown cause in which fibrous (scar) tissue forms in the lungs;
- adults and children above the age of 6 years with systemic sclerosis-associated interstitial lung disease (ILD), a disease in which the immune system (the body's natural defences) is overactive, causing development of fibrous tissue and progressive scarring of the lungs;
- adults with other chronic interstitial lung diseases that are fibrosing (causing production of fibrous tissue) and progressive (getting worse);
- children aged 6 to 17 years with clinically significant, progressive fibrosing ILDs.

Ofev contains the active substance nintedanib.

Expand section

Collapse section

## How is Ofev used?

Ofev can only be obtained with a prescription, and treatment should be started by a doctor experienced in the diagnosis and treatment of the diseases it is used for. For children, treatment should be started only after involvement of a multidisciplinary team (physicians, radiologists, pathologists) experienced in the diagnosis and treatment of ILDs.

Ofev is available as capsules taken twice a day with food, approximately 12 hours apart. In patients who do not tolerate this dose, the doctor should reduce the dose or interrupt treatment.

Children receiving Ofev will undergo dental examinations at least every six months until their teeth are fully developed, and their growth will be monitored annually through bone imaging.

For more information about using Ofev, see the package leaflet or contact your doctor or pharmacist.

## How does Ofev work?

The active substance in Ofev, nintedanib, blocks the activity of some enzymes known as tyrosine kinases. These enzymes are present in certain receptors (such as VEGF, FGF and PDGF receptors) in cells in the lungs, where they activate several processes involved in the generation of fibrous tissue. By blocking these enzymes, nintedanib helps to reduce the formation of fibrous tissue in the lungs, thereby helping to prevent worsening of the disease symptoms.

## What benefits of Ofev have been shown in studies?

Ofev has been compared with placebo (a dummy treatment) in four main studies involving a total of 1,066 adults with IPF, 580 adults with systemic sclerosis-associated ILD and 663 adults with progressive fibrosing ILD. In all studies, the main measure of effectiveness was the decline in the functioning of the patients' lungs over the course of 1 year of treatment, measured by their forced vital capacity (FVC). FVC is the maximum amount of air a person can breathe out forcefully after taking in a deep breath and decreases as the condition gets worse.

In 2 studies involving adults with IPF, patients taking Ofev had a smaller decline in FVC than patients taking placebo, meaning that Ofev slowed down the worsening of the condition. The average FVC before treatment was between 2,600 and 2,700 millilitres (ml). In the first study, the average decrease in FVC over 1 year was 115 ml in patients taking Ofev compared with 240 ml in patients taking placebo. In the second study, the average decrease was 114 ml for Ofev compared with 207 ml for placebo. A further analysis of the results of the 2 main studies, which took into account that some patients stopped treatment, confirmed the benefits of Ofev over placebo, although the difference in FVC between the two was less pronounced.

In the study involving adult patients with systemic sclerosis-associated ILD, the average decrease in FVC was 52 ml for Ofev compared with 93 ml for placebo. The average FVC before treatment was around 2,500 ml.

In the study in adults with progressive fibrosing ILD, the average decrease in FVC was 81 ml for Ofev compared with 188 ml for placebo. The average FVC before treatment was around 2,330 ml.

In addition, data in children with fibrosing ILD aged 6 to 17 years showed that, at the recommended doses, blood levels of the medicine were similar to those seen in adults at the recommended doses.

## What are the risks associated with Ofev?

For the full list of side effects and restrictions with Ofev, see the package leaflet.

The most common side effects with Ofev (which may affect more than 1 in 10 people) include diarrhoea, nausea (feeling sick), vomiting, abdominal pain (belly ache), decreased appetite and raised levels of liver enzymes in the blood (a sign of liver problems). Weight loss (which may affect up to 1 in 10 people) is also common.

Ofev must not be used in patients who are hypersensitive (allergic) to nintedanib, peanut or soya, or any of the other ingredients. Ofev must also not be used in pregnant women.

## Why is Ofev authorised in the EU?

The European Medicines Agency decided that Ofev's benefits are greater than its risks and it can be authorised for use in the EU. The Agency considered that Ofev is effective at slowing down the worsening of lung function in adult patients with IPF, systemic sclerosis-associated ILD and other chronic fibrosing ILDs that are progressive.

Based on the disease characteristics and how the medicine works, the medicine's effectiveness for treating clinically significant progressive fibrosing ILD and systemic sclerosis-associated ILD in children is expected to be similar as in adults. However, long-term safety data for children are not available and there are uncertainties on the potential impact on growth and tooth development, which require regular monitoring.

Regarding safety, the side effects associated with Ofev were considered manageable with dose interruptions or reductions.

## What measures are being taken to ensure the safe and effective use of Ofev?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ofev have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Ofev are continuously monitored. Side effects reported with Ofev are carefully evaluated and any necessary action taken to protect patients.

## Other information about Ofev

Ofev received a marketing authorisation valid throughout the EU on 14 January 2015.

Ofev : EPAR - Medicines overview

Reference Number: EMA/66511/2025

English (EN) (111.58 KB - PDF)

**First published:** 13/02/2015

**Last updated:** 10/03/2025

[View](/en/documents/overview/ofev-epar-medicines-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-268)

български (BG) (136.37 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/bg/documents/overview/ofev-epar-medicines-overview_bg.pdf)

español (ES) (112.39 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/es/documents/overview/ofev-epar-medicines-overview_es.pdf)

čeština (CS) (132 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/cs/documents/overview/ofev-epar-medicines-overview_cs.pdf)

dansk (DA) (111.74 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/da/documents/overview/ofev-epar-medicines-overview_da.pdf)

Deutsch (DE) (112.64 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/de/documents/overview/ofev-epar-medicines-overview_de.pdf)

eesti keel (ET) (111.42 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/et/documents/overview/ofev-epar-medicines-overview_et.pdf)

ελληνικά (EL) (141.71 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/el/documents/overview/ofev-epar-medicines-overview_el.pdf)

français (FR) (112.91 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/fr/documents/overview/ofev-epar-medicines-overview_fr.pdf)

hrvatski (HR) (127.55 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/hr/documents/overview/ofev-epar-medicines-overview_hr.pdf)

italiano (IT) (112.12 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/it/documents/overview/ofev-epar-medicines-overview_it.pdf)

latviešu valoda (LV) (133.33 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/lv/documents/overview/ofev-epar-medicines-overview_lv.pdf)

lietuvių kalba (LT) (130.37 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/lt/documents/overview/ofev-epar-medicines-overview_lt.pdf)

magyar (HU) (126.88 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/hu/documents/overview/ofev-epar-medicines-overview_hu.pdf)

Malti (MT) (132.11 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/mt/documents/overview/ofev-epar-medicines-overview_mt.pdf)

Nederlands (NL) (112.54 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/nl/documents/overview/ofev-epar-medicines-overview_nl.pdf)

polski (PL) (132.41 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/pl/documents/overview/ofev-epar-medicines-overview_pl.pdf)

português (PT) (132.59 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/pt/documents/overview/ofev-epar-medicines-overview_pt.pdf)

română (RO) (129.24 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/ro/documents/overview/ofev-epar-medicines-overview_ro.pdf)

slovenčina (SK) (130.06 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/sk/documents/overview/ofev-epar-medicines-overview_sk.pdf)

slovenščina (SL) (126.37 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/sl/documents/overview/ofev-epar-medicines-overview_sl.pdf)

Suomi (FI) (112.06 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/fi/documents/overview/ofev-epar-medicines-overview_fi.pdf)

svenska (SV) (111.53 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/sv/documents/overview/ofev-epar-medicines-overview_sv.pdf)

Ofev : EPAR - Risk Management Plan

English (EN) (2.24 MB - PDF)

**First published:** 26/06/2023

**Last updated:** 10/03/2025

[View](/en/documents/rmp/ofev-epar-risk-management-plan_en.pdf)

## Product information

Ofev : EPAR - Product Information

English (EN) (1.49 MB - PDF)

**First published:** 13/02/2015

**Last updated:** 28/03/2025

[View](/en/documents/product-information/ofev-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-762)

български (BG) (1.39 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/bg/documents/product-information/ofev-epar-product-information_bg.pdf)

español (ES) (1.47 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/es/documents/product-information/ofev-epar-product-information_es.pdf)

čeština (CS) (1.59 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/cs/documents/product-information/ofev-epar-product-information_cs.pdf)

dansk (DA) (1.4 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/da/documents/product-information/ofev-epar-product-information_da.pdf)

Deutsch (DE) (1.46 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/de/documents/product-information/ofev-epar-product-information_de.pdf)

eesti keel (ET) (1.4 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/et/documents/product-information/ofev-epar-product-information_et.pdf)

ελληνικά (EL) (1.63 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/el/documents/product-information/ofev-epar-product-information_el.pdf)

français (FR) (1.52 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/fr/documents/product-information/ofev-epar-product-information_fr.pdf)

hrvatski (HR) (1.34 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/hr/documents/product-information/ofev-epar-product-information_hr.pdf)

íslenska (IS) (1.46 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/is/documents/product-information/ofev-epar-product-information_is.pdf)

italiano (IT) (1.5 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/it/documents/product-information/ofev-epar-product-information_it.pdf)

latviešu valoda (LV) (1.42 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/lv/documents/product-information/ofev-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.42 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/lt/documents/product-information/ofev-epar-product-information_lt.pdf)

magyar (HU) (1.34 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/hu/documents/product-information/ofev-epar-product-information_hu.pdf)

Malti (MT) (1.51 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/mt/documents/product-information/ofev-epar-product-information_mt.pdf)

Nederlands (NL) (1.44 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/nl/documents/product-information/ofev-epar-product-information_nl.pdf)

norsk (NO) (1.4 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/no/documents/product-information/ofev-epar-product-information_no.pdf)

polski (PL) (1.47 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/pl/documents/product-information/ofev-epar-product-information_pl.pdf)

português (PT) (1.44 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/pt/documents/product-information/ofev-epar-product-information_pt.pdf)

română (RO) (1.51 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/ro/documents/product-information/ofev-epar-product-information_ro.pdf)

slovenčina (SK) (1.43 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/sk/documents/product-information/ofev-epar-product-information_sk.pdf)

slovenščina (SL) (1.29 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/sl/documents/product-information/ofev-epar-product-information_sl.pdf)

Suomi (FI) (1.36 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/fi/documents/product-information/ofev-epar-product-information_fi.pdf)

svenska (SV) (1.38 MB - PDF)

**First published:**

13/02/2015

**Last updated:**

28/03/2025

[View](/sv/documents/product-information/ofev-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000256380 28/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ofev : EPAR - All Authorised presentations

English (EN) (65.85 KB - PDF)

**First published:** 13/02/2015

**Last updated:** 10/03/2025

[View](/en/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-126)

български (BG) (71.77 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/bg/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_bg.pdf)

español (ES) (64.18 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/es/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_es.pdf)

čeština (CS) (69.44 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/cs/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (101.71 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/da/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (66.62 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/de/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (52.84 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/et/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (59.02 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/el/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_el.pdf)

français (FR) (55.72 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/fr/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (57.1 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/hr/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (58.06 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/is/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_is.pdf)

italiano (IT) (56.85 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/it/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (61.48 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/lv/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (62.55 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/lt/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (60.9 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/hu/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (60.29 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/mt/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (54.53 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/nl/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (66 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/no/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_no.pdf)

polski (PL) (61.02 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/pl/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_pl.pdf)

português (PT) (54.68 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/pt/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_pt.pdf)

română (RO) (57.29 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/ro/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (70.42 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/sk/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (54.77 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/sl/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (52.07 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/fi/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (67.48 KB - PDF)

**First published:**

13/02/2015

**Last updated:**

10/03/2025

[View](/sv/documents/all-authorised-presentations/ofev-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ofev Active substance nintedanib International non-proprietary name (INN) or common name nintedanib Therapeutic area (MeSH)

- Idiopathic Pulmonary Fibrosis
- Lung Diseases, Interstitial
- Pulmonary Fibrosis
- Scleroderma, Systemic

Anatomical therapeutic chemical (ATC) code L01EX09

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Ofev is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

## Authorisation details

EMA product number EMEA/H/C/003821

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see [Accelerated assessment](/node/69621) .

Marketing authorisation holder

Boehringer Ingelheim International GmbH

Binger Strasse 173 55216

Opinion adopted 20/11/2014 Marketing authorisation issued 14/01/2015 Revision 28

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ofev : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.1 KB - PDF)

**First published:** 28/03/2025

[View](/en/documents/procedural-steps-after/ofev-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ofev : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (169.55 KB - PDF)

**First published:** 24/02/2016

**Last updated:** 28/03/2025

[View](/en/documents/procedural-steps-after/ofev-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Ofev-H-C-003821-X-0057-G : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/2963/2025

English (EN) (6.77 MB - PDF)

**First published:** 10/03/2025

[View](/en/documents/variation-report/ofev-h-c-003821-x-0057-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Ofev (X-57-G)

Adopted

Reference Number: EMA/CHMP/512578/2024

English (EN) (91.65 KB - PDF)

**First published:** 13/12/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ofev-x-57-g_en.pdf)

Ofev : EPAR - Paediatric investigation plan compliance statement

Reference Number: EMA/CHMP/269668/2023

English (EN) (92.35 KB - PDF)

**First published:** 01/08/2023

[View](/en/documents/pip-compliance/ofev-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

Ofev-H-C-PSUSA-00010319-202010 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/493579/2021

English (EN) (125.14 KB - PDF)

**First published:** 02/09/2021

[View](/en/documents/scientific-conclusion/ofev-h-c-psusa-00010319-202010-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Ofev-H-C-003821-II-0027 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/315975/2020

English (EN) (5.11 MB - PDF)

**First published:** 28/07/2020

[View](/en/documents/variation-report/ofev-h-c-003821-ii-0027-epar-assessment-report-variation_en.pdf)

Ofev : Orphan maintenance assessment report (post-authorisation)

Adopted

Reference Number: EMADOC-1700519818-459924

English (EN) (440.33 KB - PDF)

**First published:** 09/06/2020

[View](/en/documents/orphan-maintenance-report-post/ofev-orphan-maintenance-assessment-report-post-authorisation_en.pdf)

CHMP post-authorisation summary of positive opinion for Ofev (II-27)

Adopted

English (EN) (135.23 KB - PDF)

**First published:** 29/05/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ofev-ii-27_en.pdf)

Ofev-H-C-003821-II-0026 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/155527/2020

English (EN) (5.17 MB - PDF)

**First published:** 08/05/2020

[View](/en/documents/variation-report/ofev-h-c-003821-ii-0026-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Ofev (II-26)

Adopted

Reference Number: EMA/CHMP/102818/2020

English (EN) (107.82 KB - PDF)

**First published:** 28/02/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ofev-ii-26_en.pdf)

Ofev-H-C-PSUSA-00010319-201810 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/256307/2019

English (EN) (70.11 KB - PDF)

**First published:** 13/09/2019

[View](/en/documents/scientific-conclusion/ofev-h-c-psusa-00010319-201810-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Ofev-H-C-PSUSA-00010319-201710 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/524247/2018

English (EN) (72.5 KB - PDF)

**First published:** 02/08/2018

**Last updated:** 02/08/2018

[View](/en/documents/scientific-conclusion/ofev-h-c-psusa-00010319-201710-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Ofev-H-C-PSUSA-00010319-201604 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/94652/2017

English (EN) (69.83 KB - PDF)

**First published:** 14/02/2017

**Last updated:** 14/02/2017

[View](/en/documents/scientific-conclusion/ofev-h-c-psusa-00010319-201604-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Ofev-H-C-PSUSA-00010319-201504 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/747382/2015

English (EN) (67.89 KB - PDF)

**First published:** 24/02/2016

**Last updated:** 24/02/2016

[View](/en/documents/scientific-conclusion/ofev-h-c-psusa-00010319-201504-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Ofev : EPAR - Public assessment report

Adopted

Reference Number: EMA/76777/2015

English (EN) (1.03 MB - PDF)

**First published:** 13/02/2015

**Last updated:** 13/02/2015

[View](/en/documents/assessment-report/ofev-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ofev

Adopted

Reference Number: EMA/CHMP/683189/2014

English (EN) (74.32 KB - PDF)

**First published:** 21/11/2014

**Last updated:** 21/11/2014

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ofev_en.pdf)

#### News on Ofev

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2024) 13/12/2024

[First treatment recommended for rare progressive lung conditions in children and adolescents](/en/news/first-treatment-recommended-rare-progressive-lung-conditions-children-adolescents) 13/12/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-may-2020) 29/05/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-february-2020) 28/02/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 November 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-november-2014) 21/11/2014

#### More information on Ofev

Outcome of application to extend use of Ofev (nintedanib)

Reference Number: EMA/279846/2023

English (EN) (125.45 KB - PDF)

**First published:** 23/06/2023

[View](/en/documents/medicine-qa/outcome-application-extend-use-ofev-nintedanib_en.pdf)

This product is no longer an orphan medicine. It was originally designated an orphan medicine for the following orphan indications:

- [treatment of idiopathic pulmonary fibrosis](/en/medicines/human/orphan-designations/eu-3-13-1123) (26/04/2013);
- [treatment of systemic sclerosis](/en/medicines/human/orphan-designations/eu-3-16-1724) (26/08/2016).

Ofev was withdrawn from the Community register of orphan medicinal products in May 2020 upon request of the marketing authorisation holder at the time of the granting of a change to the terms of the marketing authorisation.

#### More information on Ofev

- [EMEA-001006-PIP02-15 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001006-pip02-15)
- [EMEA-001006-PIP03-16 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001006-pip03-16)
- [EMEA-001006-PIP05-18-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001006-pip05-18-m01)
- [Post-marketing Surveillance of Ofev Capsules in Chronic (PMS for PF-ILD) - post-authorisation study](https://catalogues.ema.europa.eu/study/40512)
- [Non-interventional prospective study in patients with pulmonary fibrosis treated with nintedanib participating in a patient support program in Spain, to describe patient satisfaction with the program and to monitor quality of life. BALANCE Study - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000550)
- [Observational, multicentre, prospective, real-world post-authorization safety study describing the achievement of nintedanib-associated DIArrhoea control after 12 weeks of follow-up in patients with idiopathic puLmonary FIBrosis (IPF) and progressive pulmonary fibrosis (other than IPF) in Spain: the DIALFIB study - post-authorisation study](https://catalogues.ema.europa.eu/study/106525)
- [The special drug use-results survey (All-Case Surveillance) of Ofev® Capsules in patients with Idiopathic Pulmonary Fibrosis (IPF) in Japan - post-authorisation study](https://catalogues.ema.europa.eu/study/39448)
- [The special drug use-results survey (All-Case Surveillance) of Ofev® Capsules in patients with Idiopathic Pulmonary Fibrosis (IPF) in Japan - post-authorisation study](https://catalogues.ema.europa.eu/study/39448)
- [Prospective observational investigation of possible correlations between change in FVC and change in cough or dyspnea scores using the living with pulmonary fibrosis questionnaire (L-PF) between baseline and after approximately 52 weeks of nintedanib treatment in patients suffering from chronic fibrosing ILD with a progressive phenotype. (INREAL) - post-authorisation study](https://catalogues.ema.europa.eu/study/46027)
- [A regulatory requirement non-interventional study to monitor the safety and effectiveness of Ofev (Nintedanib, 150mg/100mg, BID) in Korean patients - post-authorisation study](https://catalogues.ema.europa.eu/study/47414)
- [A prospective, observational study on the correlations between change in lung function and change in cough and dyspnoea in patients with connective tissue disease-associated progressive fibrosing INTErstitial luNg diseaSE (CTD associated PF-ILD) treated with nintedanib (INTENSE) - post-authorisation study](https://catalogues.ema.europa.eu/study/49654)
- [Post-marketing Surveillance (PMS) on long term use of Ofev Capsules in Systemic Scleroderma associated Interstitial Lung Disease (SSc-ILD) in Japan (PMS for Ofev (SSc-ILD)) - post-authorisation study](https://catalogues.ema.europa.eu/study/45827)
- [A Phase I trial to investigate the effect of nintedanib on the pharmacokinetics of a combination of ethinylestradiol and levonorgestrel in female patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) (1199-0340) - post-authorisation study](https://catalogues.ema.europa.eu/study/40027)
- [Non-Interventional Collecting Evidences For ILD in Taiwan: Optimized Novel Therapy (NICEFIT ON) - post-authorisation study](https://catalogues.ema.europa.eu/study/37650)
- [A multicentre, retrospective chart review study to describe the clinical profile of idiopathic pulmonary fibrosis (IPF) patients treated with nintedanib (OFEV®) in real-world practice in Spain (BROAD) - post-authorisation study](https://catalogues.ema.europa.eu/study/32078)
- [Real-World Medication Adherence Trajectories to Nintedanib among Idiopathic Pulmonary Fibrosis Patients - post-authorisation study](https://catalogues.ema.europa.eu/study/42912)
- [Post Authorization Safety Study of Nintedanib in the treatment of patients with Idiopathic Pulmonary fibrosis in Argentina - post-authorisation study](https://catalogues.ema.europa.eu/study/18151)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 28/03/2025

## Share this page

[Back to top](#main-content)